Acute Myeloid Leukemia
Moleculin Biotech Inc. focuses its clinical research on acute myeloid leukemia, with studies in adults who have refractory or relapsed AML and in patients receiving first-line therapy.
- Remission induction
- Relapsed leukemia
- Refractory disease
The sponsor’s research activity centers on treatment settings where disease control remains difficult, especially in adult hematologic malignancy care.
Liposomal Annamycin and Cytarabine
Its trials examine liposomal annamycin in combination with cytarabine for AML, including use alongside standard remission-induction regimens and comparison against placebo combinations.
- Combination chemotherapy
- Anthracycline-based treatment
- Standard backbone therapy
These studies reflect a therapeutic interest in integrating a liposomal formulation with established cytotoxic therapy for leukemia treatment.
Treatment Response in AML
The sponsor’s clinical program evaluates complete remission outcomes and overall safety and tolerability in adults treated for acute myeloid leukemia.
- Complete remission
- Safety assessment
- Tolerability
Research attention is directed toward therapeutic benefit in patients needing effective remission-induction therapy.
Multicenter Hematology Research
Moleculin Biotech Inc. supports multicenter studies across several countries and collaborating sites, with active recruitment in a broad international clinical network.
- Adult oncology
- International site collaboration
- Hematology-focused enrollment
The sponsor’s clinical footprint is concentrated in blood cancer research conducted through coordinated treatment centers.
